Pivotal Studies Shaping the Ovarian Cancer Treatment Landscape Post-SGO 2022

In October, the U.S. Food and Drug Administration fast-tracked several drugs in oncology. Here are highlights in lung, brain, and ovarian cancer and more.

Phase 3 data show that lymphadenectomy can and should be skipped for certain patients with advanced epithelial ovarian cancer.

A panel of experts at the NCCN annual meeting provided an update on ongoing cancer drug shortages and called for collaborative action and systemic reforms.

ESMO, ESGO, and ESP recently published consensus recommendations for ovarian cancer from a panel of experts across 15 countries, including the United States.

The FDA fully approved mirvetuximab soravtansine for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Evaluating MRD with second-look laparoscopy found more patients with ovarian cancer who had MRD than ctDNA assays; ctDNA had greater prognostic discrimination.

The 2024 SGO Annual Meeting on Women’s Cancer centers on the power of shared purpose. This year’s event has a shorter schedule but more science, organizers say.

The FDA has granted de novo marketing authorization for Invitae’s Common Hereditary Cancers Panel, a DNA test to assess predisposition for various cancer types.

With cancer drug shortages forcing rationing and causing widespread concern, ASCO and SGO have issued new disease-specific clinical guidance.

Trastuzumab deruxtecan showed activity in two pan-tumor trials and objective responses in various cancer types.

The role of mirvetuximab soravtansine in platinum-resistant ovarian cancer care is now firmly established, as new data show improvement in overall survival.

Interim results show that durvalumab plus olaparib added to standard care improves PFS in newly diagnosed advanced ovarian cancer without BRCA mutation.